₹892.8*
MRP ₹992
10% off
₹843.2*
MRP ₹992
15% CB
₹148.8 cashback(15%)
Free Delivery
With Circle membership
(Inclusive of all Taxes)
This offer price is valid on orders above ₹800. Apply coupon PHARMA10/PHARMA18 (excluding restricted items)
Available Offers
PHARMA18PHARMA10PHARMA20
Prescription drugWhats That
Secure Payment
India's Most Trusted Pharmacy
Genuine Products
Extra Savings
संरचना :
निर्माता/विपणक :
उपभोग का प्रकार :
वापसी नीति :
इस तारीख को या बाद में समाप्त :
Drug-Drug Interactions
Drug-Drug Interactions
Login/Sign Up
Co-administration of Sorafenib with Carbopa 150mg Vial can increase the risk or severity of serious side effects.
How to manage the interaction:
Taking Sorafenib with Carbopa 150mg Vial together is not recommended as it can cause an interaction, consult a doctor before taking it. However if you experience any unusual symptoms, consult the doctor. Do not stop using any medications without consulting a doctor.
Using Adalimumab with Carbopa 150mg Vial can increase the risk of developing serious infections.
How to manage the interaction:
Although taking Carbopa 150mg Vial and Adalimumab together can cause an interaction, it can be taken if your doctor has suggested it. However, if you experience fever, chills, diarrhea, sore throat, muscle pains, breathing difficulty, blood in your coughing fluid, weight loss, red or irritated skin, body sores, and discomfort or burning sensation when you urinate, consult a doctor. Do not stop using any medications without a doctor's advice.
Taking Carbopa 150mg Vial with Clozapine may enhance the risk of serious infection.
How to manage the interaction:
Co-administration of Carbopa 150mg Vial with clozapine can possibly result in an interaction, but it can be taken if your doctor has advised it. However, if you experience fever, chills, diarrhea, sore throat, muscular pains, shortness of breath, blood in phlegm(mucous secretion), red or irritated skin, body sores, or discomfort or burning during urination, consult a doctor immediately. Do not discontinue any medications without consulting a doctor.
Using cladribine and Carbopa 150mg Vial together can increase the risk of serious infections.
How to manage the interaction:
Co-administration of Carbopa 150mg Vial and cladribine can possibly result in an interaction, but it can be taken if your doctor has advised it. However, If you experience fever, chills, diarrhea, sore throat, muscular pains, shortness of breath, blood in phlegm, red or inflamed skin, body sores, or discomfort or burning during urination, consult a doctor immediately. Do not discontinue any medications without consulting a doctor.
Taking Carbopa 150mg Vial and bacitracin can increase the risk of nephrotoxicity(kidney damage).
How to manage the interaction:
Co-administration of Carbopa 150mg Vial and bacitracin can possibly result in an interaction, but it can be taken if your doctor has advised it. However, if you experience any unusual symptoms consult the doctor. Do not discontinue any medications without a doctor's advice.
Using Carbopa 150mg Vial with Deferiprone, can increase the risk of developing serious infections.
How to manage the interaction:
There may be a possibility of interaction between Carbopa 150mg Vial and Deferiprone, but it can be taken if prescribed by a doctor. However, if you experience fever, chills, diarrhea, sore throat, muscle pains, breathing difficulty, blood in your coughing fluid, red or irritated skin, body sores, and discomfort or burning sensation when you urinate, consult a doctor. Do not stop using any medications without a doctor's advice.
When Carbopa 150mg Vial is used with topotecan, it may increase the risk of side effects.
How to manage the interaction:
Co-administration of Carbopa 150mg Vial with clozapine can possibly result in an interaction, but it can be taken if your doctor has advised it. However, if you experience any unusual symptoms, consult the doctor. Do not discontinue any medications without consulting your doctor.
Taking Carbopa 150mg Vial with Natalizumab can increase the risk of developing serious infections. Particularly, progressive multifocal leukoencephalopathy(a rare but serious viral infection of the brain).
How to manage the interaction:
Taking Carbopa 150mg Vial with Natalizumab together can possibly result in an interaction, but it can be taken if your doctor has advised it. However, if you experience fever, chills, diarrhea, sore throat, muscle pains, breathing difficulty, blood in your coughing fluid, red or irritated skin, body sores, and discomfort or burning sensation when you urinate, weakness on one side of the body, clumsiness of legs and hands, eye problems, confusion, or changes in thinking, memory and personality, consult a doctor. Do not stop using any medications without a doctor's advice.
Coadministration of baricitinib and Carbopa 150mg Vial can raise your risk of developing serious infections.
How to manage the interaction:
Although there is an interaction, baricitinib can be taken with Carbopa 150mg Vial if prescribed by the doctor. However, if you experience fever, chills, diarrhoea, sore throat, muscular aches, shortness of breath, blood in your coughing fluid, weight loss, red or irritated skin, body sores, and discomfort or burning when you urinate, consult a doctor. Do not discontinue any medications without a doctor's advice.
Taking cidofovir with Carbopa 150mg Vial can increase the risk of kidney problems.
How to manage the interaction:
Although taking Carbopa 150mg Vial and cidofovir together can possibly cause an interaction, it can be taken if your doctor has suggested it. However, if you experience loss of hunger, increased or decreased urination, swelling, shortness of breath, bone pain, muscle cramps, irregular heart rhythm, consult a doctor immediately. It is advised to wait at least for 7 days after stopping Carbopa 150mg Vial, before taking Cidofovir. Do not stop using any medications without talking to a doctor.
Drug-Food Interactions
Drug-Food Interactions
Login/Sign Up
CARBOPA 150MG VIAL Substitute
Celcarb 150 mg Injection 1's
by Others
₹892.80per tabletAlcarb 150 Injection 15 ml
by Others
₹58.68per tabletBiocarb 150 mg Injection 15 ml
by Others
₹58.20per tabletCarbotero Injection 15 ml
by Others
₹59.52per tabletCarbowel 150 mg Injection 1's
by Others
₹769.12per tablet
Product Substitutes
शराब
सावधानी
कार्बोपा 150एमजी शीशी लेते समय आपको शराब के सेवन से बचने की सलाह दी जाती है। इससे अप्रिय दुष्प्रभावों से बचा जा सकता है।
गर्भावस्था
असुरक्षित
कार्बोपा 150एमजी शीशी का उपयोग गर्भावस्था के दौरान नहीं किया जाना चाहिए क्योंकि इससे भ्रूण (नवजात शिशु) को नुकसान होता है। बच्चे पैदा करने की क्षमता वाली महिलाओं और पुरुषों दोनों को कार्बोपा 150एमजी शीशी लेते समय और उसके बाद कम से कम छह महीने तक एक प्रभावी गर्भनिरोधक विधि का उपयोग करना चाहिए। इस बारे में किसी भी चिंता के लिए कृपया अपने डॉक्टर से सलाह लें।
स्तनपान
असुरक्षित
कार्बोपा 150एमजी शीशी का सेवन स्तनपान के दौरान नहीं करना चाहिए क्योंकि यह मां के दूध में चला जाता है और दूध पीने वाले बच्चे को नुकसान पहुंचा सकता है। यह स्तनपान कराने वाली माताओं में contraindicated है। इस बारे में किसी भी चिंता के लिए कृपया अपने डॉक्टर से सलाह लें।
ड्राइविंग
सावधानी
कार्बोपा 150एमजी शीशी आपकी प्रतिक्रियाओं और ड्राइव करने की आपकी क्षमता को प्रभावित कर सकता है। कार्बोपा 150एमजी शीशी के साथ कीमोथेरेपी के संभावित दुष्प्रभाव हो सकते हैं, जैसे मतली और उल्टी। यदि आप इन दुष्प्रभावों से प्रभावित हैं, तो आपको गाड़ी नहीं चलाना चाहिए और/या ऐसी मशीनें नहीं चलानी चाहिए जिनके लिए आपको सतर्क रहने की आवश्यकता होती है।
जिगर
सावधानी
यदि आपको लीवर से संबंधित किसी भी बीमारी का इतिहास या सबूत है, तो कृपया कार्बोपा 150एमजी शीशी लेने से पहले डॉक्टर से परामर्श लें। आपका डॉक्टर आपको यह दवा देने से पहले इसके फायदे और किसी भी संभावित जोखिम का आकलन करेगा।
गुर्दा
सावधानी
यदि आपको गुर्दे से संबंधित किसी भी बीमारी का इतिहास या सबूत है, तो कृपया कार्बोपा 150एमजी शीशी लेने से पहले डॉक्टर से परामर्श लें। आपका डॉक्टर आपको यह दवा देने से पहले इसके फायदे और किसी भी संभावित जोखिम का आकलन करेगा।
बच्चे
असुरक्षित
प्रभावकारिता और सुरक्षा स्थापित नहीं की गई है। कृपया अपने डॉक्टर से सलाह लें। आपका डॉक्टर उन्हें निर्धारित करने से पहले लाभों और संभावित जोखिमों का वजन करेगा।
Disclaimer
Author Details
